Nektar Therapeutics (NKTR)
1.46
0.00 (0.00%)
USD |
NASDAQ |
Apr 30, 16:00
1.45
-0.01
(-0.68%)
After-Hours: 20:00
Nektar Therapeutics Cash from Investing (Quarterly): 17.38M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 17.38M |
| September 30, 2023 | 56.41M |
| June 30, 2023 | 25.17M |
| March 31, 2023 | 40.60M |
| December 31, 2022 | 40.01M |
| September 30, 2022 | 111.40M |
| June 30, 2022 | 84.15M |
| March 31, 2022 | 130.28M |
| December 31, 2021 | 120.20M |
| September 30, 2021 | -0.83M |
| June 30, 2021 | 72.95M |
| March 31, 2021 | 10.46M |
| December 31, 2020 | 92.74M |
| September 30, 2020 | 48.67M |
| June 30, 2020 | 157.04M |
| March 31, 2020 | 197.77M |
| December 31, 2019 | 135.48M |
| September 30, 2019 | 58.25M |
| June 30, 2019 | 25.29M |
| March 31, 2019 | -12.14M |
| December 31, 2018 | 87.54M |
| September 30, 2018 | -621.27M |
| June 30, 2018 | -894.42M |
| March 31, 2018 | 48.21M |
| December 31, 2017 | 22.98M |
| Date | Value |
|---|---|
| September 30, 2017 | -80.69M |
| June 30, 2017 | 41.97M |
| March 31, 2017 | -13.07M |
| December 31, 2016 | -142.10M |
| September 30, 2016 | 28.38M |
| June 30, 2016 | -4.923M |
| March 31, 2016 | 36.25M |
| December 31, 2015 | -7.205M |
| September 30, 2015 | 5.705M |
| June 30, 2015 | -65.99M |
| March 31, 2015 | 53.16M |
| December 31, 2014 | -24.81M |
| September 30, 2014 | 40.15M |
| June 30, 2014 | 5.302M |
| March 31, 2014 | -58.21M |
| December 31, 2013 | -82.15M |
| September 30, 2013 | 41.78M |
| June 30, 2013 | 46.60M |
| March 31, 2013 | 43.69M |
| December 31, 2012 | 62.23M |
| September 30, 2012 | -5.391M |
| June 30, 2012 | 7.759M |
| March 31, 2012 | 48.42M |
| December 31, 2011 | 14.40M |
| September 30, 2011 | 52.73M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-0.83M
Minimum
Sep 2021
197.77M
Maximum
Mar 2020
74.92M
Average
58.25M
Median
Sep 2019
Cash from Investing (Quarterly) Benchmarks
| Stereotaxis Inc | 0.00 |
| Vanda Pharmaceuticals Inc | -43.78M |
| Cara Therapeutics Inc | -30.20M |
| Avid Bioservices Inc | -4.488M |
| Rigel Pharmaceuticals Inc | -6.874M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -47.05M |
| Cash from Financing (Quarterly) | 0.012M |
| Free Cash Flow | -193.47M |
| Free Cash Flow Per Share (Quarterly) | -0.2475 |
| Free Cash Flow to Equity (Quarterly) | -47.28M |
| Free Cash Flow to Firm (Quarterly) | -44.94M |
| Free Cash Flow Yield | -69.75% |